Bioprocess Development Forum - Insights, Solutions, and Shortcuts in Bioprocessing
BioPharm
Sponsored by Cytiva
Biopharma Trends
Upstream
Downstream
Regulatory/QbD
Articles
Subscribe to Enews
Share This Page
Email
Facebook
Twitter
July 29, 2021
Cytiva and Pall Corporation Investing 1.5 Billion USD Over Two Years to Meet Growing Demand for Biotechnology Solutions
Cytiva
Click here to read more >>
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers.
Related Content
The Evolution of Supply Chain Security: Increasing Focus on Raw Material Variability
Applying GMPs to the BioPharma Supply Chain
Securing Today’s Biomanufacturing Supply Chain Using Transformative Supply
Supply Chain Challenges for Single-Use Systems
Managing Risk in Raw Material Sourcing
See All Articles…
